Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE study of immediate endocrine therapy versus chemotherapy followed by endocrine therapy in pre/perimenopausal hormone receptor-positive early breast cancer
NL-OMON25775Recruiting
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Jul 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of goserelin, anastrozole, cyclophosphamide, epirubicin and fluorouracil in breast cancer (2 arms), sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Relapse-free survival. Started Jul 2005; status: recruiting.
02
Drugs
goserelinanastrozolecyclophosphamideepirubicinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON25775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25775.